Malfertheiner, P., Bazzoli, F., Delchier, J.C., et al. (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin based triple therapy: A randomised, open-label, non-in feriority, phase 3 trial. Lancet, 377, 905-913. doi:10.1016/S0140-6736(11)60020-2

has been cited by the following article:

• TITLE: Therapy for H. pylori: Current concepts

  AUTHORS: Giulia Fiorini, Angelo Zullo, Valentina Castelli, Chiara Ricci, Giovanna Lo Re, Ilaria Saracino, Cristina Zaccaro, Federico Maria Verardi, Alessandra Reggi, Dino Vaira

  KEYWORDS: Helicobacter pylori; Sequential Therapy; Eradication

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.3 No.1, February 28, 2013

  ABSTRACT: Helicobacter pylori plays an important role in the pathogenesis of chronic active gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue-lymphoma, and is also involved in carcinogenesis of the stomach. Since now no current first-line therapy is able to cure the infection in all treated patients. We evaluated data on the most successful therapy regimens—sequential, concomitant and quadruple therapies—and on the standard therapy available for H. pylori eradication. When therapy fails several factors may be involved: we reviewed both bacterial and host factors that can affect the eradication and that can be involved in therapeutic management of the H. pylori infection.